ARGENX UK LTD
Get an alert when ARGENX UK LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-08-24 (in 3mo)
Last made up 2025-08-10
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£15M
Equity attributable
Employees
46
Average over period
Profit before tax
£2M
Period ending 2024-12-31
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £14,232,125 | £20,185,810 | |
| Operating profit | £1,096,353 | £2,350,402 | |
| Profit before tax | £1,094,005 | £2,316,984 | |
| Net profit | £1,313,349 | £2,217,161 | |
| Cash | — | — | |
| Total assets less current liabilities | £6,748,299 | £14,779,170 | |
| Net assets | £6,748,299 | £14,779,170 | |
| Equity | £6,748,299 | £14,779,170 | |
| Average employees | 40 | 46 | |
| Wages | £4,632,757 | £7,010,905 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 7.7% | 11.6% | |
| Net margin | 9.2% | 11.0% | |
| Return on capital employed | 16.2% | 15.9% | |
| Gearing (liabilities / total assets) | 55.3% | 22.5% | |
| Current ratio | 1.81x | 4.44x | |
| Interest cover | 59.31x | 63.43x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Having considered the company's solid financial performance, growth in sales, substantial current assets, and the availability of the support committed by its parent organization, the directors are satisfied that the company has access to sufficient funds to support its operations within the going concern period.”
Significant events
- “In January 2025, the National Institute for Health and Care Excellence (NICE) declined to recommend Vyvgart for NHS use in MG, citing gaps in evidence regarding cost-effectiveness, despite acknowledging the product's potential clinical benefit. Argenx appealed the decision, but the appeal was unsuccessful following an independent panel review on 6 May 2025. As a result, the focus has now shifted toward preparing for commercial launch in CIDP over the coming years.”
- “The company has written off its entire FY2024 inventory due to rejection by NICE (National Institute for Health and Care Excellence). The products, labelled specifically for the UK market, cannot be sold without NICE approval.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 3 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BAUER, Marc Christian, Dr | Director | 2024-12-07 | Oct 1976 | German |
| KNECHTEL, Pierre David | Director | 2022-08-11 | Jan 1973 | Canadian |
Show 3 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| MAZARS COMPANY SECRETARIES LIMITED | Corporate Secretary | 2022-08-11 | 2023-02-11 |
| HAUWERMEIREN, Tim Joris M. Van | Director | 2022-08-11 | 2022-08-11 |
| MURTHY, Ananthram | Director | 2022-08-11 | 2024-12-07 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Argenx Se | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-08-11 | Active |
Filing timeline
Last 12 of 12 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-21 | AA | accounts | Accounts with accounts type full | |
| 2025-09-01 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-01-16 | AP01 | officers | Appoint person director company with name date | |
| 2025-01-15 | TM01 | officers | Termination director company with name termination date | |
| 2024-08-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-08-19 | AA | accounts | Accounts with accounts type full | |
| 2023-08-18 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-02-28 | TM02 | officers | Termination secretary company with name termination date | |
| 2022-10-05 | TM01 | officers | Termination director company with name termination date | |
| 2022-09-27 | AA01 | accounts | Change account reference date company current extended | |
| 2022-09-09 | CH01 | officers | Change person director company with change date | |
| 2022-08-11 | NEWINC | incorporation | Incorporation company |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31